You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,186,414

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,186,414

Title:	Composition for intraocular implantation of bevacizumab
Abstract:	A solid, compressed pharmaceutical composition comprises i) a peptide active pharmaceutical ingredient, ii) a polysaccharide excipient and/or an albumin, and iii) an oligosaccharide excipient. The polysaccharide excipient may be hyaluronic acid, or the potassium salt thereof, and the oligosaccharide excipient may be trehalose.
Inventor(s):	Khaw; Peng T. (London, GB), Brocchini; Stephen (London, GB), Khalili; Ashkan (Addison, IL)
Assignee:	UCL Business PLC (London, GB)
Application Number:	13/878,375
Patent Claims:	1. A solid, compressed pharmaceutical composition comprising i) a peptide active pharmaceutical ingredient, ii) a polysaccharide excipient, and iii) an oligosaccharide excipient, wherein the polysaccharide excipient is present in the form of a potassium salt thereof. 2. A composition according to claim 1, wherein the oligosaccharide excipient is a non-reducing sugar. 3. A composition according to claim 1, wherein the oligosaccharide excipient is a disaccharide. 4. A composition according to claim 1, wherein the oligosaccharide excipient is trehalose. 5. A composition according to claim 1, wherein the polysaccharide excipient is non-sulphated. 6. A composition according to claim 1, wherein the polysaccharide excipient is a glycosaminoglycan. 7. A composition according to claim 6, wherein the polysaccharide excipient is hyaluronic acid. 8. A composition according to claim 1, wherein the composition contains one or more further, pharmaceutically acceptable excipients. 9. A composition according to claim 8, wherein the one or more further pharmaceutically acceptable excipients comprises an albumin. 10. A composition according to claim 1 wherein the composition contains potassium ions which are present as a potassium salt. 11. A composition according to claim 1, wherein the composition is sterile. 12. A composition according to claim 1, wherein the peptide active pharmaceutical ingredient, polysaccharide excipient, and oligosaccharide excipient are freeze dried, optionally in the presence of a potassium buffer salt. 13. A composition according to claim 12, wherein the peptide active pharmaceutical ingredient, polysaccharide excipient and oligosaccharide excipient are freeze dried together. 14. A composition according to claim 1, in the form of a tablet. 15. A composition according to claim 1, wherein the peptide active pharmaceutical ingredient has a molecular weight of around 0.5 kDa to around 250 kDa. 16. A composition according to claim 1, wherein the peptide active pharmaceutical ingredient is an antibody or an antigen-binding fragment thereof. 17. A composition according to claim 16, wherein the antibody is an anti-VEGF antibody. 18. A composition according to claim 1, wherein the composition is coated. 19. A composition according to claim 1, which is suitable for implantation. 20. A compressed pharmaceutical composition comprising a peptide active pharmaceutical ingredient, and potassium salt, wherein the potassium salt comprises the potassium salt of hyaluronic acid. 21. A composition according to claim 20, wherein the composition further comprises albumin. 22. A composition according to claim 1, containing one or more additional active pharmaceutical ingredients. 23. A method for the treatment or prevention of a condition selected from scarring, tumour growth and/or metastasis, vasculoproliferative conditions, conditions involving neovascularisation, vascular endothelial cell proliferation, angiogenesis, disorders of the eye selected from diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration and choroidal neovascularisation, or for the treatment of a tumour that may be selected from brain tumour, breast tumour, kidney tumour, colorectal tumour, lung tumour, prostate tumour, head and neck tumours, stomach tumour, pancreatic tumour, skin tumour, cervical tumour, bone tumour, ovarian tumour, testicular tumour and liver tumours, the method comprising the implantation, into a suitable site of a subject in need of such treatment or prevention, of a composition according to claim 1. 24. A method for the treatment of neoplastic conditions, macular degeneration, diabetic retinopathy, or corneal angiogenesis, or for the prevention of scarring following glaucoma filtration surgery, the method comprising the implantation, into a suitable site of a subject in need of such treatment or prevention, of a composition according to claim 17. 25. A composition according to claim 17, wherein the antibody is bevacizumab. 26. A composition according to claim 10,wherein the potassium ions present as a potassium salt are present as a potassium buffer salt.

Details for Patent 9,186,414

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2030-10-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.